Skip to content
Master Your Financial Future — Master Your Money — Financial Insights Unveiled

Kura Oncology's Q3 2025 Earnings Call: No Major Announcements, Leadership Updates Clinical Progress

No significant new collaborations or projects, but analysts engaged with Kura's leadership to discuss financials and pipeline progress.

,   and  Administrator
1 min read
At the bottom of the picture, we see two men and a woman are sitting on the chairs. In front of...
At the bottom of the picture, we see two men and a woman are sitting on the chairs. In front of them, we see a man in the black blazer is standing and he is talking on the microphone. Beside him, we see a flower pot or a flower bouquet. Beside that, we see a table on which a book, water bottle and some other objects are placed. Behind him, we see a podium on which the microphones are placed. In the background, we see a brown wall and a board in white, blue and red color with some text written on it. This picture might be clicked in the conference hall.

Kura Oncology's Q3 2025 Earnings Call: No Major Announcements, Leadership Updates Clinical Progress

Kura Oncology, Inc. (KURA) hosted its Q3 2025 Earnings Call on November 4, 2025, with key executives and analysts from various research firms participating. The call was led by Greg Mann and featured presentations from Troy Wilson, Tom Doyle, Mollie Leoni, and Brian Powl. The call provided an update on Kura Oncology's progress and plans. However, there was no announcement of a new significant collaboration agreement or development project that had not been previously disclosed. The analysts who joined the call included Li Wang Watsek (Cantor Fitzgerald & Co.), Jason Zemansky (BofA Securities), Yue-Wen Zhu (LifeSci Capital, LLC), Salim Syed (Mizuho Securities USA LLC), Philip Nadeau (TD Cowen), Reni Benjamin (Citizens JMP Securities, LLC), and Alexandre Bouilloux (Barclays Bank PLC). They likely discussed the company's financial performance, clinical trials, and pipeline. Kura Oncology's Q3 2025 Earnings Call offered insights into the company's operations and strategies. While no new major security agreements were announced, the call provided an opportunity for analysts and investors to engage with the company's leadership and gain updates on its ongoing work in oncology.

Read also:

Related

Latest